Coya Therapeutics (NASDAQ:COYA) Announces Quarterly Earnings Results

Coya Therapeutics (NASDAQ:COYA) issued its quarterly earnings results on Tuesday. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10), FiscalAI reports. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%. The business had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.11 million.

Coya Therapeutics Stock Up 0.9%

COYA stock traded up $0.03 during trading on Tuesday, hitting $3.36. 33,871 shares of the company’s stock traded hands, compared to its average volume of 178,726. Coya Therapeutics has a 52 week low of $2.72 and a 52 week high of $6.62. The stock has a fifty day moving average price of $4.40 and a two-hundred day moving average price of $4.61. The stock has a market capitalization of $78.83 million, a price-to-earnings ratio of -3.14 and a beta of 0.70.

Analyst Upgrades and Downgrades

COYA has been the topic of a number of recent research reports. Roth Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of Coya Therapeutics in a research report on Monday, August 24th. HC Wainwright reissued a “buy” rating on shares of Coya Therapeutics in a research report on Friday, September 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Thursday, October 15th. Chardan Capital restated a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a report on Wednesday, August 12th. Finally, BTIG Research restated a “buy” rating and set a $16.00 target price on shares of Coya Therapeutics in a report on Tuesday, September 15th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Coya Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $15.00.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune activity, and the company is studying their potential to address neurodegenerative diseases and other conditions involving inflammation and immune dysfunction.

The company’s lead investigational program, COYA 101, is an autologous Treg cell therapy being evaluated for amyotrophic lateral sclerosis (ALS). The treatment is designed to use a patient’s own regulatory T cells, which are expanded and functionally enhanced outside the body before being administered.